Global Congenital Heart Disease Market - Strategic Insights and Forecasts (2026-2031)

The Global Congenital Heart Disease market is projected to grow from USD 5.32 billion in 2026 to USD 7.86 billion by 2031. This represents a Compound Annual Growth Rate (CAGR) of 8.12% over the forecast period, reflecting significant expansion in the diagnostic, surgical, and long-term management sectors.

The market is shaped by surgical correction technologies, catheter-based interventions, cardiac rhythm management systems, and advanced imaging platforms. There's a notable trend toward minimally invasive transcatheter procedures, increasing the adoption of structural heart closure devices, transcatheter pulmonary valves, and AI-assisted imaging systems.

Rising neonatal and pediatric survival rates are a primary driver, significantly expanding the adult congenital heart disease population. This transition creates increased long-term demand for repeat interventions, specialized adult management programs, and lifelong cardiac monitoring technologies, shifting healthcare systems toward continuous cardiac surveillance.

The shift towards minimally invasive transcatheter interventions is reducing procedural risk, shortening intensive care utilization, and improving long-term functional outcomes in pediatric populations. This trend is increasing the adoption of structural heart closure devices and transcatheter pulmonary valves, moving the market from isolated surgical correction to longitudinal disease management.

Investment in specialized pediatric cardiac infrastructure is expanding due to the high healthcare dependency generated by congenital heart disease. Regulatory systems further support this growth through pediatric device approvals, orphan disease incentives, and accelerated pathways for structural heart technology, fostering innovation to address pediatric cardiovascular morbidity.

The market is evolving from isolated surgical correction toward a comprehensive longitudinal disease management model. This involves increasing dependency on repeat interventions, advanced diagnostic imaging, rhythm management devices, and lifelong cardiac monitoring systems, especially as patient survival rates continue to rise across age cohorts.